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Recombinant poxviruses have shown promise as vaccine vectors. We hypothesized that improved cellular immune responses could be
developed to a foreign antigen by incorporating it as part of the extracellular enveloped virion (EEV). We therefore constructed a recombinant
vaccinia virus that replaced the cytoplasmic domain of the B5R protein with a test antigen, HIV-1 Gag. Mice immunized with the virus
expressing Gag fused to B5R had significantly better primary CD4 T-cell responses than recombinant virus expressing HIV-Gag from the
TK-locus. The CD8 T-cell responses were less different between the two groups. Importantly, although we saw differences in the immune
response to the test antigen, the vaccinia virus-specific immune responses were similar with both constructs. When groups of vaccinated mice
were challenged 30 days later with a recombinant Listeria monocytogenes that expresses HIV-Gag, mice inoculated with the virus that
expresses the B5R-Gag fusion protein had lower colony counts of Listeria in the liver and spleen than mice vaccinated with the standard
recombinant. Thus, vaccinia virus expressing foreign antigen incorporated into EEV may be a better vaccine strategy than standard
recombinant vaccinia virus.
D 2004 Elsevier Inc. All rights reserved.Keywords: Vaccinia virus; Recombinant vaccine; EEV; B5R chimeric protein; HIV; Gag; Cellular immune response; Listeria monocytogenes; Heterologous
challenge
Introduction roll et al., 1998; Honda et al., 1998; Kaufman et al., 2002;Recombinant poxviruses have shown promise as ef-
fective vaccine vectors because of their ability to prime
adaptive immune responses to expressed foreign antigens.
Enhancement of the immune response to the foreign antigen
has been pursued as a way to further improve vaccine
efficacy. Approaches to augment the immune response have
ranged from the co-expression of cytokines or other immune
modulating molecules along with the foreign antigen (Car-0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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College of Physicians and Surgeons, 177 Fort Washington Avenue, New
York, NY 10032.McLaughlin et al., 1997; Rodriguez et al., 1999; Sivanand-
ham et al., 1998) to prime-boost strategies (e.g., (Amara et
al., 2001; Oh et al., 2003)). In recent years, there has been
interest in incorporating the foreign antigen as part of the
vaccinia virus particle (Barchichat and Katz, 2002; Katz et
al., 1997).
The majority of poxvirus-based vaccines produce anti-
gens that remain in the cytoplasm, are secreted, or are
expressed on the outer membrane of infected cells. En-
hancing the immune response through expression of for-
eign antigens on particles or virions has been shown in
other systems (Allsopp et al., 1996; Beneduce et al., 2002;
Casal, 1999; Evans et al., 1989; Mandl et al., 1998; Ulrich
et al., 1998). For example, particles of hepatitis B virus
when used to carry foreign epitopes induced protective B
and T-cell immune responses against the inserted antigens
(Ulrich et al., 1998). For poxviruses, a single study
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HIV-1 envelope glycoprotein on the surface of the extra-
cellular enveloped virus (EEV) induced higher HIV-spe-
cific antibody responses in mice than a standard vaccinia
virus vector expressing an unmodified HIV glycoprotein
that is not trafficked to EEV (Katz and Moss, 1997).
Cellular immune responses to this antigen have not been
investigated.
The B5R protein is one of a group of EEV-specific
proteins encoded by vaccinia virus (Engelstad and Smith,
1993; Engelstad et al., 1992; Isaacs et al., 1992; Martinez-
Pomares et al., 1993; Smith et al., 2002; Takahashi-
Nishimaki et al., 1991; Wolffe et al., 1993). Specific
domains of B5R are dispensable for EEV formation,
allowing for the generation of B5R chimeras that target
proteins to EEV (Herrera et al., 1998; Katz et al., 1997;
Lorenzo et al., 1998; Mathew et al., 1998, 2001; Rodger
and Smith, 2002). We and others have shown that EEV is
still formed in the absence of the cytoplasmic tail of the
B5R protein (Lorenzo et al., 1998; Mathew et al., 1999,
2001). For this study, we substituted the cytoplasmic
domain of the B5R protein with a foreign protein, HIV-1
Gag, and found that Gag was specifically incorporated into
EEV. T-cell responses to the B5R-Gag chimera were
enhanced and conferred better protection from a heterolo-
gous challenge compared to a standard recombinant vac-
cinia virus that does not incorporate Gag into EEV. Thus,
this report is the first to illustrate that cellular immunity to
a foreign antigen is improved when that antigen is
expressed as part of EEV.Fig. 1. Growth curves of viruses at low and high multiplicities of infection. Conflue
At the indicated time points, virus contained in the media (A and C) or cell lysa
dashed line: rVV-TK/Gag; closed triangle: wild-type virus.Results
Expression of B5R-Gag fusion protein results in
incorporation of Gag into EEV
We successfully constructed and isolated a recombinant
vaccinia virus (strain IHDJ) that replaced the cytoplasmic
tail of the B5R protein with the HIV-Gag sequence. The
resulting virus (rVV-B5R/Gag) generated smaller plaques
under semisolid overlay. Growth curves at low and high
multiplicity of infection (m.o.i.) showed that when com-
pared to wild-type virus (WT) or the control virus that
expresses HIV-Gag from the TK-locus (rVV-TK/Gag), rVV-
B5R/Gag released approximately 10 times less virus in the
media (Figs. 1A and C). Growth curves of cell-associated
virus by wild type, rVV-TK/Gag, and rVV-B5R/Gag were
similar (Figs. 1B and D). Thus, despite the decreased
amount of released virus by rVV-B5R/Gag, at low m.o.i.,
enough virus is being released to efficiently spread the virus
in tissue culture. Western blotting with anti-B5R antibody of
infected cell lysate from the recombinant virus producing a
chimeric B5R/Gag protein showed a fusion protein of the
predicted molecular weight (approximately 85 kDa) (data
not shown). When the blot was stripped and probed with a
rabbit polyclonal antiserum to Gag, the same 85-kDa band
was seen (data not shown). To determine the amount of Gag
antigen synthesized by the rVV-B5R/Gag and rVV-TK/Gag,
we quantitated Gag/p24 levels in infected cell lysates. rVV-
TK/Gag produced moderately higher (4–6) levels of Gag
than rVV-B5R/Gag (data not shown). This is likely due tont BSC-1 cells were infected at an m.o.i. of 0.005 (A and B) or 5 (C and D).
te (B and D) were titered. Open squares: rVV-B5R/Gag; open circles with
Fig. 3. Western blot of EEV. The proteins contained in EEV from the
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Gag. Cesium chloride gradients of media from metabolical-
ly labeled cells infected with the viruses revealed that rVV-
B5R/Gag produced EEV at levels about 5-fold lower than
wild type (Fig. 2). Western blotting of EEV released into the
media of infected cells with an anti-Gag antibody revealed
that rVV-B5R/Gag incorporated Gag into the virion, al-
though wild type and rVV-TK/Gag did not (Fig. 3).
Vaccinia virus-specific immune responses to rVV-B5R/Gag
and rVV-TK/Gag are identical
rVV-B5R/Gag and rVV-TK/Gag are genetically distinct
recombinant viruses. Vaccinia viruses with an inactivated
TK gene are attenuated (Buller et al., 1985). Because the
standard recombinant vaccinia virus expressing Gag has an
inactivated TK gene and the recombinant vaccinia virus
expressing B5R/Gag has an intact TK gene, we examined
the vaccinia virus-specific immune responses of each re-
combinant virus between ensure that differences we found
to the Gag-specific immune responses (see below) did not
result from an improved immune response to all antigens in
one vaccine vs. the other. Cell-mediated immunity, as
measured by IFN-g production, antigen-specific prolifera-
tion, and cytotoxic T lymphocyte (CTL)-mediated target cellFig. 2. Quantitation of EEV released from infected cells by cesium chloride
gradient centrifugation. Confluent RK-13 cells were infected with (A) rVV-
B5R/Gag or (B) wild type (IHDJ) virus in the presence of S-35 cysteine and
methionine. Twenty-four hours postinfection, media was placed over a
CsCl gradient and spun at approximately 111,000  g for 3 h. Fractions
were collected from the bottom of the tube and the radioactivity was
counted in a scintillation counter (closed squares). The density (open
circles) of alternating fractions was determined to confirm that the peak
activity was similar.
media of cells infected with wild-type virus (WT) or the recombinant virus
expressing Gag fused to B5R (B5R/Gag) or Gag expressed in the TK
region (TK/Gag) were resolved by SDS-PAGE, transferred to nitrocellu-
lose, and probed with anti-Gag antibody. Arrow to the right indicates the
B5R-Gag fusion protein. Numbers on the left refer to the molecular masses
(in kilodaltons). To confirm that approximate equal amounts of EEV were
loaded in each lane, the blot was stripped and probed with an anti-P37
antibody (lower blot).lysis, was equivalent between rVV-B5R/Gag and rVV-TK/
Gag immunized mice (Figs. 4A–C). The antibody
responses mounted against each recombinant virus were
also comparable (Fig. 4D). It should be noted that the cell-
mediated and humoral immune responses elicited in re-
sponse to both recombinant viruses were significantly
reduced from those mounted against WT virus (data not
shown). Thus, rVV-B5R/Gag and rVV-TK/Gag generate
equivalent vector-specific immune responses. To determine
whether the weakened virulence of the recombinant viruses
impaired their ability to confer protective immunity to
vaccinia virus challenge, we immunized mice with rVV-
B5R/Gag or rVV-TK/Gag. After 1 month, we challenged
the mice with a lethal dose of vaccinia and measured weight
loss over time. Although unimmunized mice succumbed to
disease between 4 and 6 days postinfection, vaccinated
animals were rendered equally resistant (Fig. 4E).
Gag-specific CD4+ T-cell proliferative responses is
improved in mice immunized with rVV-B5R/Gag
To measure Gag-specific CD4+ T-cell proliferation, we
incubated splenocytes from rVV-B5R/Gag, rVV-TK/Gag, or
Fig. 4. Vaccinia-specific immune responses. Splenocytes from immunized mice were harvested 2 weeks after vaccination and co-cultured with naı¨ve antigen-
presenting cells (APC) that had been infected with WT virus (INF APC) or left uninfected (unINF APCs). (A) IFN-g ELISpot. (B) Antigen-specific
proliferation measured by BrdU incorporation. (C) CTL responses were determined by restimulating splenocytes with vaccinia for 6 days. Cells were
harvested, labeled with Calcein AM, and co-cultured with infected P815 targets at 50:1, 25:1, 12.5:1 (splenocyte/target) ratio. After 3 h, Calcein release was
quantitated using a fluorometer and percentage of specific lysis determined. (D) Anti-vaccinia virus antibody responses in sera from mice immunized 2 weeks
earlier were measured by ELISA. Absorbance values of serum samples correspond to a 1/30 dilution. (E) Immunized mice are protected from a vaccinia
challenge. BALB/c mice were unimmunized or immunized intraperitoneally with rVV-B5R/Gag, rVV-TK/Gag, or WT virus. Mice were challenged
intranasally with 2  106 pfu of WT virus (strain WR) and the percentage of weight loss calculated over time. Shown are the means F SEM of individual mice
for each condition. Each experiment was performed twice with similar results.
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peptide (Mata and Paterson, 1999) and quantitated prolifer-
ation by a colorimetric assay. Pigeon cytochrome C peptide
(a class II peptide) and con-A were used as controls.
Splenocytes from all three immunized groups responded
well to con-A, with a specific index (S.I.) well above 15, but
did not respond to irrelevant control peptide (data notshown). However, splenocytes from mice immunized with
rVV-B5R/Gag showed significantly improved proliferation
in response to class II Gag-specific peptide than those from
mice immunized with rVV-TK/Gag (P < 0.0001) (Fig 5).
Thus, immunization with a virus in which the foreign
antigen was incorporated into the virion elicited a statisti-
cally better CD4+ T-cell proliferation response.
Fig. 5. Gag-specific CD4+ T-cell proliferative responses from immunized mice. Ten days after immunization, splenocytes of mice immunized with rVV-B5R/
Gag or rVV-TK/Gag or wild-type control virus were incubated with class II Gag peptide for 48 h. Stimulation Index (S.I.) was calculated as O.D. with antigen/
O.D. without antigen. Five mice were in each group per experiment and result shown is the representative from three separate experiments. Error bars represent
standard deviation (rVV-B5R/Gag vs. rVV-TK/Gag, P < 0.0001; rVV-B5R/Gag vs. wild type, P < 0.0001; rVV-TK/Gag vs. wild type, P = 0.1813).
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IFN-c secreting CD4+ T-cell precursors
To investigate the effects of immunization of rVV-B5R/
Gag on CD4+ and CD8+ T-cell responses, we stimulated
splenocytes with either class II- or class I-specific Gag
peptides and quantitated the number of IFN-g producing
cells by ELISpot. The cells producing IFN-g appeared as
dark blue spots representing Gag-specific IFN-g producing
effector cells. Mice vaccinated with rVV-B5R/Gag had
significantly more Gag-specific IFN-g secreting CD4+ T
cells than those from mice vaccinated with rVV-TK/Gag
(P < 0.0001) (Fig. 6A). In contrast, the number of Gag-
specific CD8+ T cells making IFN-g was similar between
the two groups (P = 0.3) (Fig. 6B). Our data suggest thatFig. 6. Gag-specific IFN-g ELISpot assay of splenocytes from immunized mice. G
type control virus and 10 days later splenocytes were plated (A, 5  105 splenocyt
plates with either (A) class II Gag peptide and stimulated overnight or (B) class I
was counted. Five mice were in each group per experiment and results were averag
rVV-B5R/Gag vs. rVV-TK/Gag: (A) P < 0.0001; (B) P = 0.3416. In the absence of
the CD4 and CD8 assay, respectively.Gag incorporation within the virus virion enhances CD4+
T-cell-induced effector function.
rVV-B5R/Gag immunization produced more IFN-c in
response to class II-specific Gag peptide
We were also interested in whether the type of T-helper
cell response differed between the groups of vaccinated
mice. The production of IFN-g and IL-4 was measured as
a correlate of Th1- vs. Th2-type cytokine responses, respec-
tively. Ten days after immunization, splenocytes were har-
vested and incubated with Gag MHC class II or class I
peptides and the supernatants were collected at various time
points. CD4+ and CD8+ T cells produced significant levels of
IFN-g, but very little IL-4, indicating a predominant Th1-roups of mice were immunized with rVV-B5R/Gag or rVV-TK/Gag or wild-
es/well; B, 2.5  105 splenocytes/well) into IFN-g antibody-coated ELISpot
Gag peptide. Secreted IFN-g was detected and the number of colored spots
ed from three separate experiments. Error bars represent standard deviation.
antigen, 0.08% and 0.016% of cells were spontaneously secreting IFN-g in
Fig. 7. Gag-specific cytokine ELISA of splenocytes from immunized mice. Ten days after immunization, splenocytes were isolated and incubated with either
(A) class II Gag peptide or (B) class I Gag peptide. At 6, 24, and 48 h after the incubation, supernatants were collected and production of IFN-g and IL-4 was
measured by ELISA. Three mice were in each group per experiment and the experiment was carried out three separate times. The data shown are representative
results. Open squares: rVV-B5R/Gag; open circles with dashed line: rVV-TK/Gag; closed triangle: wild-type virus. Error bars representing standard deviation
were smaller than the symbols and thus do not appear on the figure.
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Gag immunized group produced more IFN-g when stimu-
lated with class II Gag peptide compared to the rVV-TK/Gag
group (Fig. 7A). When cells were stimulated with class I Gag
peptide, however, splenocytes from the rVV-TK/Gag group
showed better IFN-g production at early time points (6 and
24 h) and similar IFN-g production at a later time point (48 h)
(Fig. 7B).Fig. 8. Heterologous challenge of vaccinated mice with recombinant Listeria expr
challenged with a recombinant Listeria expressing HIV-Gag. Shown is data for col
on day 3 after Listeria challenge. For each set of points, the horizontal line represe
and liver); rVV-B5R/Gag vs. rVV-TK/Gag: P = 0.03 and P = 0.007 (for the spleImmunization with rVV-B5R/Gag protects mice in a
heterologous challenge model
To determine if the enhanced Gag-specific cellular
immune responses elicited by rVV-B5R/Gag would corre-
late with improved protection, we challenged groups of
vaccinated mice with a recombinant Listeria that expresses
HIV-Gag (Lm-Gag). This experimental strategy of immu-essing HIV-Gag. Thirty days after vaccinia virus immunization, mice were
ony counts in the homogenized spleen and liver from each mouse sacrificed
nts the mean [rVV-B5R/Gag vs. rVV-control: P = 0.007 (for both the spleen
en and liver, respectively)].
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carrying the same recombinant antigen is similar to
approaches used to test non-vaccinia virus-based vaccines
(Belyakov et al., 1999; Mata et al., 2001; Rayevskaya and
Frankel, 2001). Similar to our approach, this type of
protection assay has also been specifically used to study
vaccinia vaccination followed by Listeria challenge (An et
al., 1996). Thirty days after a single vaccinia virus immu-
nization, groups of mice were challenged with 0.2 LD50 of
Lm-Gag. At various times after challenge, groups of mice
were sacrificed and the colony counts of Listeria were
determined in the spleen and liver. At day 3 post challenge
(Fig. 8), there were significantly lower colony counts in
the spleen and liver of mice immunized with rVV-B5R/
Gag when compared to mice.Discussion
Improving the immunogenicity of poxvirus vaccine
vectors is important when considering issues of safety
and efficacy of such vaccines. One approach to improve
immune responses to foreign antigens, which has not been
extensively explored with poxviruses, is to manipulate the
site of foreign antigen expression. To date, the majority of
poxvirus-based vaccines produce antigens that either re-
main in the cytoplasm, are secreted from infected cells, or
are expressed on the outer membrane of infected cells.
Directed incorporation of foreign antigens into the vaccinia
virion is distinct from the inclusion on the virion of some
host antigens that has been identified to happen during
viral morphogenesis (Gomez and Esteban, 2001; Krauss et
al., 2002; Vanderplasschen et al., 1998). Our knowledge of
the structure–function relationship of domains of the EEV-
specific B5R protein allowed us to construct a recombinant
virus that specifically incorporated a foreign antigen into
EEV. We made the recombinant viruses in a strain of
vaccinia virus (i.e., IHDJ) that releases relatively high
amounts of EEV (Payne, 1980). The resulting recombinant
virus (rVV-B5R/Gag) made smaller plaques under semi-
solid overlay and released less EEV than wild type. This
result differs from the studies using a recombinant vaccinia
virus that fused GFP to the cytoplasmic tail of B5R and
made plaques similar in size to the wild-type virus (Ward
and Moss, 2001). The differences in plaque size between
these two recombinant viruses may have multiple explan-
ations. The Gag protein that we fused to B5R is about
twice the size of GFP. Alternatively, there may be protein–
protein interactions between Gag fused to B5R. Finally, as
opposed to the GFP construct, our construct deletes the
cytoplasmic tail.
Antigen expression on particles or virions has been
explored in other systems (Allsopp et al., 1996; Casal,
1999; Evans et al., 1989; Mandl et al., 1998; Ulrich et al.,
1998). Antigens presented on particles may result in en-
hanced immunity for several reasons. HIV-envelope dis-played on EEV (Katz and Moss, 1997) may enhance the
humoral immune response due to its presentation as a
particulate, polyvalent form, rather than a monomeric pro-
tein (Ulrich et al., 1998). We hypothesized that directly
incorporating a foreign antigen into a vaccinia virion would
improve the cellular immune response by allowing released
virions containing the antigen to be directly taken up by
antigen-presenting cells (APC). In such a form, the APC
could begin to directly process the foreign antigen that was
engulfed as part of the virion resulting in augmented T-
helper cell responses. In addition, delivery of an antigen in
the context of a virion might supply the necessary ‘‘danger’’
signal required to produce an antigen-specific immune
response (Gallucci and Matzinger, 2001). The released
virions could also produce newly synthesized antigen within
the APC, similar to standard vaccinia virus vaccine vectors.
Our findings of improved CD4-helper responses and en-
hanced protection in a heterologous challenge model sup-
port this hypothesis. Although HIV-Gag expressed by itself
is known to self-assemble into particles (Gheysen et al.,
1989; Karacostas et al., 1989), we did not include a portion
of the N-terminus of Gag in the recombinant viruses to
compare the immune responses to a foreign antigen specif-
ically incorporated into EEV with a standard recombinant
vaccinia virus that did not incorporate the foreign antigen
into the virion (or release foreign antigen particles). Because
a dramatic loss of CD4+ T cells is associated with HIV
infection, our finding that rVV-B5R/Gag elicits enhanced T-
helper cell responses (with a Th1 bias) may aid in designing
preventative and therapeutic vaccines against HIV. Further-
more, because the recombinant virus that expresses a
chimeric B5R protein forms smaller plaques and has slightly
altered growth characteristics in tissue culture, it may have
an improved safety profile when compared to a standard
vector.
Because the test construct and the standard recombinant
vaccinia virus vector were genetically different (i.e., they
had differences in their TK and B5R genes), a concern
might be that the enhanced Gag-specific immune response
to rVV-B5R/Gag (mutated B5R gene/TK+) was due to that
virus being a better overall immunogen than rVV-TK/Gag
(wild-type B5R gene/TK  ). However, we found that
vaccinia virus-specific immune responses to each recom-
binant virus were essentially identical. Another potential
concern is that because the two viruses under study
express Gag from different promoters, the rVV-B5R/Gag
may be expressing more protein and thus provide a better
immune response to the antigen (Hemmer et al., 1998;
Wherry et al., 1999). However, although rVV-B5R/Gag
induces a more potent immune response to Gag, this
recombinant synthesized lower levels of antigen than the
standard recombinant vector (rVV-TK/Gag). The strong
synthetic early/late promoter (Chakrabarti et al., 1997)
used to express Gag in the rVV-TK/Gag results in the
production of more protein than the natural B5R promoter
used by rVV-B5R/Gag. In total, these findings support our
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rated into EEV enhances the immune response to the
foreign protein when compared to a standard recombinant
vaccinia virus.
Because primary CD8+ T-cell responses were similar
between rVV-B5R/Gag and the standard recombinant vector
(rVV-TK/Gag), the protection seen after Listeria challenge
may indicate that CD4+ T-cell responses are important for
the control of Listeria infection. The role of CD4+ T cells in
controlling Listeria infections is somewhat controversial.
Some studies suggest that they play no role in protection
against Listeria challenge (Baldridge et al., 1990; Mielke et
al., 1988, 1989), whereas others suggest that both CD4+ and
CD8+ T cells are important (Kaufmann et al., 1985; Ladel et
al., 1994; Sasaki et al., 1990). There are also many studies
claiming that CD4+ T cells alone can mediate clearance of
Listeria (Bhardwaj et al., 1998; Magee and Wing, 1988;
Rakhmilevich, 1994; Sasaki et al., 1990). CD4+ T-cell-
mediated clearance of Listeria may be possible for low-
challenge doses with Listeria, but CD8+ T cells must play a
critical role in clearing fulminant infections, because, in
addition to infecting MHC class II positive cells such as
macrophages and other APCs, Listeria also infects class II
negative cells such as hepatocytes. In an attempt to dem-
onstrate that CD4+ T-cell responses are important for the
control of Listeria infection in our system, before Listeria
challenge, we depleted CD4+ or CD8+ cells from groups of
mice using standard protocols (Mata et al., 2001). However,
the isotype control antibody altered the Listeria counts in
control animals thus making it difficult to interpret data
from vaccinated animals that are then depleted. The effect
the control antibody had on Listeria infection may have
been caused by nonspecific macrophage activation that
facilitated early control of the Listeria infection.Materials and methods
Plasmid constructs used to generate recombinant viruses
We constructed a transfer plasmid (pSI-169g) that en-
abled in-frame cloning of Gag into the B5R ORF that
replaces the B5R cytoplasmic tail. The plasmid contains
the natural B5R promoter region for early/late expression
(Engelstad et al., 1992) of the chimeric protein, the natural
B5R signal peptide (Isaacs et al., 1992) to direct the
chimeric protein to the secretory pathway, flanking vaccinia
virus sequences that directs insertion into the B5R region of
vaccinia virus by homologous recombination (Earl and
Moss, 1991), and an efficient way to isolate recombinant
viruses by a positive selection procedure (Isaacs et al.,
1990). A fragment of Gag from the HXB2 clone of
prototype HIV strain 3B (from amino acid 29 to 498) was
generated by PCR using appropriate primers that allowed
in-frame cloning into the pSI-169g. We chose this portion of
Gag because it correlated exactly with the segmentexpressed by a recombinant Listeria expressing HXB2
Gag (Mata et al., 2001) that we used to challenge vaccinated
mice. Sequencing of the resulting plasmid (pSI-171k) con-
firmed that no inadvertent mutations were introduced and
transient transfection of vaccinia virus-infected cells con-
firmed that the chimeric protein was produced from pSI-
171k. To generate a standard vaccinia virus expressing HIV-
Gag, we cloned the identical HXB2 Gag fragment into
pSC65 (Chakrabarti et al., 1997). The resulting plasmid
(pSI-172-4) allows recombination into the vaccinia virus
thymidine kinase gene (TK) and the expression of the
cloned Gag to be driven by a vaccinia virus strong synthetic
early/late promoter.
Isolation of recombinant vaccinia viruses and
characterization
Recombinant viruses were generated by homologous
recombination in cells infected with a B5R deletion virus
(vSI-15) and transfected with p171k. vSI-15 was a previ-
ously isolated vaccinia virus (strain IHDJ) in which the
majority of the B5R ORF was replaced with a gpt selection
cassette (Wolffe et al., 1993). The recombinant virus-
expressing Gag fused to B5R (vSIAA-32; called rVV-
B5R/Gag in this paper) was isolated and plaque purified
by reverse gpt selection (Isaacs et al., 1990). The standard
recombinant vaccinia virus-expressing Gag was generated
by homologous recombination in cells infected with IHDJ
and transfected with pSI-172-4. This virus (vSIAA-34;
called rVV-TK/Gag in this paper) was isolated and plaque
purified following standard techniques and plaque isolation
on a TK- cell line in the presence of bromo-deoxyuridine
and x-gal (Earl and Moss, 1991). Western blots of infected
cell lysates showed that Gag is expressed and recognized by
a rabbit polyclonal antiserum to Gag, HIV-1 p25/24 Gag
antiserum (Steimer et al., 1986) (data not shown). Western
blot analysis of the Gag protein present in EEV was
performed on unlabeled virus in the media of infected cells
that was pelleted through a 36% sucrose cushion. The
amount of Gag produced by each virus was quantitated
using a P24 assay on lysates of virus infected cells. Briefly,
BSC-1 cells were infected with each virus at an m.o.i. of 1
and incubated for 20 h at 37 jC in 5% CO2. The cells were
harvested, centrifuged, and resuspended in 0.1% Triton X-
100. p24 Gag levels on diluted specimens were determined
by p24 ELISA (Coulter, Krefeld, Germany) according to the
manufacturer’s instructions. Virus growth kinetics were
measured on confluent wells of BSC cells infected at
m.o.i. of 5 pfu/cell and 0.005 pfu/cell with rVV-B5R/Gag,
rVV-TK/Gag, or wild-type virus in duplicate. At various
time points, media and cells were harvested and virus
titered. To confirm that EEV was indeed produced by the
recombinant virus expressing a chimeric B5R-Gag protein,
we carried out CsCl gradient centrifugation analysis on
metabolically labeled virus released from infected cells into
the media (Payne and Norrby, 1976).
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Female BALB/c (H-2d) mice were purchased from
Charles River Laboratories (Raleigh, NC) and maintained
in a pathogen-free microisolator environment. Mice used in
this study were 6–12 weeks old. Six- to eight-week-old
female BALB/c mice were immunized once by intraperito-
neal inoculation with approximately 2  106 pfu of recom-
binant vaccinia viruses or wild-type virus. Although tail
scarification is frequently a method of vaccinating mice, we
chose to use the intraperitoneal route because it allowed us
to use a lower dose of virus than is often used with tail
scarification and it made us more confident that the mice
were receiving the targeted dose of virus. Because we were
interested in examining the primary immune response (and
not a memory response), we sacrificed mice 10–14 days
after vaccination.
Vaccinia-specific immune responses
All assays examining vaccinia-specific immune responses
were performed with splenocyte suspensions prepared from
mice immunized 2 weeks earlier with rVV-B5R/Gag, rVV-
TK/Gag, or WT virus. Cells were enriched for lymphocytes
by plating in 6-well plates at 2 106 cells/well, incubating at
37 jC, and removing the non-adherent cells after 3 h. For
vaccinia-specific cytokine production, cells were resus-
pended in complete RPMI and IFN-g ELISpot was per-
formed using an IFN-g ELISpot kit (R&D Systems,
Minneapolis, MN) according to the manufacturer’s instruc-
tions. Briefly, 2  105 splenocytes were plated into each
well and co-cultured with 1  105 or 5  104 antigen-
presenting cells (APCs). APCs were naı¨ve splenocytes
infected for 1 h at a ratio of 3 pfu/cell with vaccinia virus
(strain WR) and irradiated. Uninfected APCs were used to
quantitate nonspecific responses. After 24 h, wells were
washed and plates were incubated overnight with a biotiny-
lated anti-IFN-g mAb. IFN-g-producing cells were detected
with alkaline phosphate-streptavidin and BCIP/NBT chro-
mogen substrate. Positive cells were quantitated using a
dissection microscope.
For vaccinia-specific cell proliferation, cells were resus-
pended in complete RPMI and 1  106 cells were plated in
96-well flat-bottomed plates and co-cultured with 5  105
restimulator cells. After 48 h, proliferation was measured by
BrdU incorporation using a cell proliferation ELISA kit
(Roche Diagnostics, Indianapolis, IN). Briefly, splenocytes
were incubated for 2 h with BrdU labeling solution. Cells
were then fixed, and proliferating cells detected using anti-
BrdU-peroxidase and tetramethyl-benzidine (TMB) sub-
strate. Absorbance was measured using an ELISA reader
at 370 nm.
For vaccinia-specific cytotoxic CD8+ T lymphocyte
responses, two-thirds of each spleen from vaccinated mice
were resuspended in complete RPMI and cultured in 75-cm
tissue culture flasks at 37 jC. The remaining third was
H. Kwak et al. / Viroresuspended in 5% FBS and infected at a ratio of 3 pfu/cell
with WR. After 1 h, the infected restimulators were added to
the cultured flasks. After 6 days, the cells were harvested
and plated in 96-well round-bottomed plates at 1  106
cells/well. Four 2 dilutions were made for each sample.
Cells were co-cultured with 2  104 target cells. Target cells
were P815 cells infected for 1 h at a ratio of 5 pfu/cell with
WR and labeled with Calcein AM (Molecular Probes,
Eugene, OR). Uninfected targets were used as controls.
After 3 h, plates were centrifuged and the supernatant
transferred into 96-well flat-bottomed Fluoro Nunc plates.
Calcein release was quantitated using a fluorometer at 538
nm emission and 485 nm excitation.
For anti-vaccinia virus antibody responses, 96-well flat-
bottomed ELISA plates were coated overnight at 4 jC using
whole cell vaccinia-infected cell lysates (Hammarlund et al.,
2003) in bicarbonate coating buffer. Briefly, 48 h after
infection with WR, infected HeLa cells were harvested, spun
down, and lysed in RIPA buffer. This material was then
diluted 1:100 in bicarbonate coating buffer and added to
plates. Serial 3-fold dilutions of sera, harvested from naı¨ve
mice or groups of mice immunized 2 weeks earlier, were
incubated for 1 h at room temperature. Plates were washed
and incubated with horseradish peroxidase-conjugated rabbit
anti-mouse IgGAM (1:2000; Zymed, San Francisco, CA).
After 1 h, samples were detected with OPD (Acros Organics,
NJ). Reaction was stopped with 1 M HCl and absorbance
measured using an ELISA reader at 490 nm.
Peptides
All of the T-cell epitopes for the H-2d mouse used in this
study have been previously defined. The Kd-restricted class
I Gag peptide is sequence 197–205 (AMQMLKETI) (Mata
et al., 1998) and the Kd-restricted control peptide is from
Listeriolysin O (LLO), sequence 91–99 (GYKDGNETI)
(Pamer et al., 1991). The H-2d restricted class II Gag peptide
is sequence 253–272 (NPPIPVGEIYKRWIILGLNK)
(Mata and Paterson, 1999). The control MHC class II
binding peptide was the pigeon cytochrome c epitope
(KAERADLIAYLKQATAK) (Schwartz, 1985).
Peptides Gag 197–205 and LLO 91–99 were purchased
as HPLC purified products from the Biopolymer Synthesis
Center, California Institute of Technology, Pasadena, CA.
All other peptides were synthesized in our laboratory using
DuPont’s RaMPS multiple peptide synthesis system proce-
dure on Wang Resin ( p-Alkoxy-benzyl Alcohol Resin)
(DuPont Chemical Company) using Fmoc (9-Fluorenylme-
thyloxycarbonyl) nitrogen terminal protected amino acids
(BACHEM Biotech Company, Philadelphia, PA). Couplings
were carried out using DPC (N-N-diisopropylcarbodiimide),
HOBT (1-Hydroxybenzotriazole) in DMF (N,N-dimethyl-
formamide) solvent and were monitored by ninhydrin reac-
tion in 100 jC water for 5 min. Simultaneous resin cleavage
and side-chain deprotection were achieved by high-concen-
tration TFA (all chemical reagents purchased from Aldrich
H. Kwak et al. / Virology 322 (2004) 337–348346and Sigma Company). All crude products were purified to
98% purity by reverse-phase high performance liquid chro-
matography (HPLC) (Perkin Elmer Series 400) using a
Vydac C18 column and their molecular weight verified by
MALDI-Mass Spectroscopy.
Gag-specific proliferation assay
Ten days after the primary immunization, groups of mice
were sacrificed and spleens were harvested. Spleens were
processed through nylon mesh and single cell suspensions
were prepared. Red blood cells were lysed and splenocytes
were resuspended in complete RPMI 1640 supplemented
with 10% FBS, 2mM L-glutamine, 100 U/ml penicillin, 100
Ag/ml streptomycin, 1 mM sodium pyruvate, and 50 AM h-
mercaptoethanol. A total of 5 105 cells were plated into 96-
well microplates in triplicate with class II Gag peptide (10 AM
final concentration) and incubated for 48 h. As controls, 10
AMof pigeon cytochrome c peptide or 1 Ag/ml of con-Awere
added. Proliferation was measured by colorimetric assay 4
h after adding WST-1 reagent (Roche Diagnostics, Ger-
many). This assay reflects the metabolic activity of a prolif-
erating cell population and when compared to BrdU and 3H-
thymidine incorporation assays gave the same results (Drew
Weissman, University of Pennsylvania; personal communi-
cation). O.D. was measured at 450 nm. Stimulation index
(S.I.) was calculated as O.D. with peptide/O.D. without
peptide.
Gag-specific IFN-c ELISpot
Splenocytes were prepared from immunized mice and
resuspended in complete RPMI and counted. IFN-g ELI-
Spot was performed using murine IFN-g ELISpot kit (R&D
Systems) following the manufacturer’s instructions. Briefly,
2.5  105 or 5  105 splenocytes were plated into each well
in duplicate and incubated with 1 AM of Gag class I epitope,
10 AM of Gag class II epitope, or control peptides at 37 jC.
Control peptides were either LLO 91–99 (1 AM) or pigeon
cytochrome c (10 AM). After 24 h, wells were washed and
secreted IFN-g was incubated with biotinylated anti-IFN-g
antibody, followed by alkaline phosphatase-conjugated
streptavidin and substrate, BCIP/NBT chromogen. Plates
were washed, dried, and colored spots were counted in
blinded fashion using dissection microscope. The numbers
of spots (approximately 40) from splenocytes immunized
with wild-type virus were subtracted from those immunized
with each recombinant virus.
Gag-specific cytokine ELISA
Splenocytes (6  106 cells/well) from immunized mice
were prepared and incubated with either class I Gag peptide
(1 AM/well) or class II Gag peptide (10 AM/well), for 6, 24,
and 48 h. At each time point, supernatants were collected and
the concentrations of IFN-g and IL-4 in supernatants weremeasured using mouse IFN-g and IL-4 ELISA kits (eBio-
science, San Diego, CA) following the manufacturer’s
instructions. Briefly, plates were coated with capture anti-
body overnight, blocked with assay diluent, and washed with
wash buffer three times. Standards and experimental super-
natants were added to appropriate wells in duplicate. Two
hours later, plates were developed with avidin-HRP and TMB
as a substrate and were read at 450 nm. The levels of IFN-g
and IL-4 were calculated by comparison with a standard
curve using murine IFN-g and murine IL-4. The lower limit
of detection for the assay was approximately 4 pg/ml.
Mouse challenge studies
To examine if vaccinated mice had different responses to
vaccinia virus challenge, groups of 6–7 weeks old BALB/c
mice were immunized intraperitoneally with rVV-B5R/Gag,
rVV-TK/Gag, or WT virus. Four weeks after immunization,
mice were challenged intranasally with 2  106 pfu of WR.
Mice were weighed before and each day following infection
and percentage of weight loss was calculated over time. To
determine if vaccinated groups could control a heterologous
challenge of an organism expressing HIV-Gag, we used a
previously described Listeria monocytogenes expressing
HIV-Gag (Lm-Gag) (Mata et al., 2001). Groups of 6- to
7-week-old female BALB/c mice were immunized intra-
peritoneally with approximately 2  106 pfu of the various
recombinant or wild-type viruses. Approximately 30 days
after immunization, mice were challenged intraperitoneally
with 1  106 cfu of Lm-Gag. At 3, 6, and 10 days, mice
were sacrificed and the liver and spleen were harvested.
Listeria colony counts were determined after homogeniza-
tion of the tissue and plating of serial dilutions of the
homogenate on BHI agar. Colonies were only detectable
on day 3. At later time points, few colonies were detectable
in the liver.
Statistical analysis
Statistical differences between groups were determined
with the Mann–Whitney test and Student’s t test.Acknowledgments
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